EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 408 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma MOST POPULAR OncoArray Links Dozens of DNA Variants to Risk for Common Cancers June 12, 2018 FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma October 20, 2020 New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines July 15, 2020 Working Outdoors in the Sunshine May Lower Your Risk of Breast... February 18, 2021 Load more HOT NEWS Impressive Responses to PD-1 Blockade in a Large Cohort of Children... What to Do If You’ve Been Diagnosed With Cancer in the... Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor...
